Anna Torgeson1, Shane Lloyd1, Dustin Boothe1, George Cannon2, Ignacio Garrido-Laguna3, Jonathan Whisenant3, Mark Lewis4, Robin Kim5, Courtney Scaife5, Randa Tao6,7. 1. Department of Radiation Oncology, University of Utah, Salt Lake City, UT, USA. 2. Department of Radiation Oncology, Intermountain Medical Center, Murray, UT, USA. 3. Department of Internal Medicine, University of Utah, Salt Lake City, UT, USA. 4. Department of Internal Medicine, Intermountain Medical Center, Murray, UT, USA. 5. Department of Surgery, University of Utah, Salt Lake City, UT, USA. 6. Department of Radiation Oncology, University of Utah, Salt Lake City, UT, USA. Randa.Tao@hci.utah.edu. 7. Huntsman Cancer Institute, 1950 Circle of Hope Drive, Room 1570, Salt Lake City, UT, 84112, USA. Randa.Tao@hci.utah.edu.
Abstract
BACKGROUND: Unresected extrahepatic cholangiocarcinoma (uEHCC) remains a deadly disease. Guidelines for uEHCC recommend either chemotherapy alone (CT) or chemoradiotherapy (CRT). This study used the National Cancer Database (NCDB) to compare outcomes for patients treated with CT and those who underwent CRT. METHODS: Patients with initially diagnosed non-metastatic uEHCC from 2004 to 2014 were identified. Using Chi square analysis, patients who underwent CT were compared with those who received CRT. Uni- and multivariate Cox regression analyses were used to compare characteristics related to survival. Propensity score matching and shared frailty analysis were undertaken to correct for baseline differences between the two groups. Additional analyses were performed to compare survival for the minority of patients who underwent surgery and advanced-stage patients. RESULTS: The study identified 2996 patients with uEHCC. Chemoradiation was associated with better survival (median survival [MS], 14.5 months; hazard ratio [HR] 0.84; p < 0.001) than CT alone (MS, 12.6 months). Induction of CT before CRT was associated with a trend toward decreased risk of death compared with concurrent CRT (HR 0.81; p = 0.051). For the patients able to undergo surgery after initial treatment, MS was 24.5 months (HR 0.38; p < 0.001) versus 12.2 months for those who had no surgery. For these patients, CRT also was associated with better survival (MS, 31.2 months; HR 0.66; p = 0.001) than CT (MS, 22.1 months). Positive margins at surgery yielded survival equivalent to that with no surgery. CONCLUSION: Although CRT may be associated with slightly better survival in uEHCC than CT alone, the majority of the benefit was observed for patients able to undergo eventual surgery.
BACKGROUND: Unresected extrahepatic cholangiocarcinoma (uEHCC) remains a deadly disease. Guidelines for uEHCC recommend either chemotherapy alone (CT) or chemoradiotherapy (CRT). This study used the National Cancer Database (NCDB) to compare outcomes for patients treated with CT and those who underwent CRT. METHODS:Patients with initially diagnosed non-metastatic uEHCC from 2004 to 2014 were identified. Using Chi square analysis, patients who underwent CT were compared with those who received CRT. Uni- and multivariate Cox regression analyses were used to compare characteristics related to survival. Propensity score matching and shared frailty analysis were undertaken to correct for baseline differences between the two groups. Additional analyses were performed to compare survival for the minority of patients who underwent surgery and advanced-stage patients. RESULTS: The study identified 2996 patients with uEHCC. Chemoradiation was associated with better survival (median survival [MS], 14.5 months; hazard ratio [HR] 0.84; p < 0.001) than CT alone (MS, 12.6 months). Induction of CT before CRT was associated with a trend toward decreased risk of death compared with concurrent CRT (HR 0.81; p = 0.051). For the patients able to undergo surgery after initial treatment, MS was 24.5 months (HR 0.38; p < 0.001) versus 12.2 months for those who had no surgery. For these patients, CRT also was associated with better survival (MS, 31.2 months; HR 0.66; p = 0.001) than CT (MS, 22.1 months). Positive margins at surgery yielded survival equivalent to that with no surgery. CONCLUSION: Although CRT may be associated with slightly better survival in uEHCC than CT alone, the majority of the benefit was observed for patients able to undergo eventual surgery.
Authors: Brady S Laughlin; Molly M Petersen; Nathan Y Yu; Justin D Anderson; William G Rule; Mitesh J Borad; Bashar A Aqel; Mohamad B Sonbol; Amit K Mathur; Adyr A Moss; Tanios S Bekaii-Saab; Daniel H Ahn; Todd A DeWees; Terence T Sio; Jonathan B Ashman Journal: J Gastrointest Oncol Date: 2022-02
Authors: Krishan R Jethwa; Shilpa Sannapaneni; Trey C Mullikin; William S Harmsen; Molly M Petersen; Phanindra Antharam; Brady Laughlin; Amit Mahipal; Thorvardur R Halfdanarson; Kenneth W Merrell; Michelle Neben-Wittich; Terence T Sio; Michael G Haddock; Christopher L Hallemeier Journal: J Gastrointest Oncol Date: 2020-12
Authors: Dalia Elganainy; Emma B Holliday; Cullen M Taniguchi; Grace L Smith; Rachna Shroff; Milind Javle; Kanwal Raghav; Ahmed Kaseb; Thomas A Aloia; Jean Nicolas Vauthey; Ching-Wei D Tzeng; Joseph M Herman; Albert C Koong; Sunil X Krishnan; Bruce D Minsky; Christopher H Crane; Prajnan Das; Eugene J Koay Journal: Cancer Med Date: 2018-08-27 Impact factor: 4.452
Authors: Lei Xu; Yang Li; Lixing Zhou; Robert Gregory Dorfman; Li Liu; Rui Cai; Chenfei Jiang; Dehua Tang; Yuming Wang; Xiaoping Zou; Lei Wang; Mingming Zhang Journal: Cancer Med Date: 2019-04-16 Impact factor: 4.452
Authors: Elaine Luterstein; Minsong Cao; James M Lamb; Ann Raldow; Daniel Low; Michael L Steinberg; Percy Lee Journal: Adv Radiat Oncol Date: 2019-10-10